| Client |
Description |
Value |
| Affymax, Inc. |
Private Placement of Preferred Stock |
$60 |
| Agensys Inc. |
Private Placement of Preferred Stock |
$43 |
| Alexza Pharmaceuticals |
Private Placement of Preferred Stock |
$52 |
| Arena |
Follow-on Public Offering |
$180 |
| Astellas Pharmaceutical Co., Ltd. |
Purchase of Agensys Inc. |
$537 |
| Cabrellis Pharmaceuticals |
Sale to Pharmion, Inc. |
$104 |
| Conatus Pharmaceuticals, Inc. |
Private Placement of Preferred Stock |
$25 |
| Conforma Therapeutics, Inc. |
Sale to Biogen Iden, Inc. |
$250 |
| Corgentech Inc. |
Private Placement of Preferred Stock |
$50 |
| Corus Pharma, Inc. |
Private Placement of Preferred Stock |
$65 |
| Eisai Co., Ltd. |
Purchase of Morphotek, Inc. |
$325 |
| Eyetech Inc. |
Private Placement of Preferred Stock |
$25 |
| Genesoft, Inc. |
Private Placement of Preferred Stock |
$22 |
| Idun Pharmaceuticals, Inc. |
Private Placement of Preferred Stock |
$66 |
| Intradigm Corporation |
Private Placement of Preferred Stock |
$21 |
| KaloBios Pharmaceuticals, Inc. |
Private Placement of Preferred Stock |
$37 |
| LigoCyte Pharmaceuticals, Inc. |
Sale to Takeda Pharmaceutical Company Limited |
$60 |
| Medicure |
PIPE |
$20 |
| Morphotek, Inc. |
Private Placement of Preferred Stock |
$40 |
| Otsuka Pharmaceutical Co., Ltd. |
Collaboration with Bristol-Myers Squibb |
NA |
| Otsuka Pharmaceutical Co., Ltd. |
Purchase of IV Busulfex from PDL BioPharma |
$200 |
| Raven Biotechnologies, Inc. |
Private Placement of Preferred Stock |
$48 |
| Raven Biotechnologies, Inc. |
Sale to MacroGenics, Inc. |
NA |
| Scios Inc. |
Sale to Johnson & Johnson |
$2,600 |
| Synta Pharmaceuticals, Inc. |
Initial Public Offering |
$50 |
| Verus Pharmaceuticals, Inc. |
Private Placement of Preferred Stock |
$40 |
| Xanthus Pharmaceuticals, Inc. |
Sale to Antisoma plc. |
$52 |
| Xenon Pharmaceuticals, Inc. |
Private Placement of Preferred Stock |
$47 |
| XenoPort, Inc. |
Private Placement of Preferred Stock |
$37 |
